Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 2
Submit an article Journal homepage
56
Views
24
CrossRef citations to date
0
Altmetric
Review

Recent developments in Neisseria meningitidis group A conjugate vaccines

Carl E Frasch Center for Biologics Evaluation and Research, Laboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, FDA, 1401 Rockville Pike, Rockville, MD 20852, USA. [email protected]
Pages 273-280 | Published online: 20 Apr 2005

Bibliography

  • FRASCH CE: Production and control of Neisseria meningitidis vaccines. In: Bacterial Vaccines. Mizrahi A (Ed.), Wiley-Liss, New York, USA (1990):123–145.
  • FRASCH CE: Meningococcal vaccines: past, present and future. In: Meningococcal Disease. Cartwright K (Ed.), Wiley, New York, USA (1995):245–283.
  • ZOLLINGER WD: New and improved vaccines against meningococcal disease. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds), Marcel Dekker, New York, USA (1997):469–488.
  • FRASCH CE, BASH MC: Neisseria meningitis vaccines. In: Bacterial Vaccines. Ellis RW, Brodeur BR (Eds), Eurekah, New York, USA (2003):228–242.
  • JODAR L, FEAVERS IM, SALISBURY D,GRANDEE DM: Development of vaccines against meningococcal disease. Lancet (2002) 359:1499–1508.
  • •Provides a good overview of recent meningococcal vaccine development.
  • GOLDSCHNEIDER I, GOTSCHLICH EC, ARTENSTEIN MS:Human immunity to the meningococcus. II. Development of natural immunity. Exp. Med. (1969) 129:1327–1348.
  • LENNON D, GELLIN B, HOOD D et al.: Successful intervention in a Group A meningococcal outbreak in Auckland, New Zealand. Pediatr. Infect. Dis. J. (1992) 11:617–623.
  • KÄYHTY H, PELTOLA H, ESKOLA Jet al.: Immunogenicity of Haemophilus injiuenzae oligosaccharide- protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. Pediatrics (1989) 84:995–999.
  • WARD J, BRENNEMAN G, LETSON GW, HEYWARD \In., ALASKA H: Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. Influenzae Vaccine Group. N Engl. J. Med. (1990) 323:1393–1401.
  • TROTTER CL, ANDREWS NJ, KACZMARSKI EB, MILLER E, RAMSEY ME: Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 364:365–367.
  • •Excellent update of conjugate effectiveness for up to 4 years and the importance of antibody versus memory.
  • BORROW R, GOLDBLATT D, ANDREWS N et al.: Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J. Infect. Dis. (2002) 186:1353–1357.
  • PELTOLA H, MAKELA PH, KAYHTY H et al.: Clinical efficacy of meningococcus group a capsular polysaccharide vaccine in children three months to five years of age. N Engl. J. Med. (1977) 297:686–691.
  • SCHNEERSON R, BARRERA O, SUTTON A, ROBBINS JB: Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. J. Exp. Med. (1980) 152: 361–376.
  • BISGARD KM, KAO A, LEAKE J et al.:Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg-. Infect. Dis. (1998) 4:1–14.
  • BEUVERY EC, KAADEN AVD, KANHAI V, LEUSSINK AB: Physiochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods. Vaccine (1983) 1:31–36.
  • JENNINGS HJ, LUGOWSKI C: Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. (1981) 127:1011–1018.
  • BERRY DS, LYNN F, LEE CH, FRASCH CE, BASH MC: Effect of 0 acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. (2002) 70:3707–3713.
  • BEUVERY EC, DELFT RV, MIEDEMA F, KANHAI V, NAGEL J: Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice. Infra. Immun. (1983) 41:609–617.
  • COSTANTINO P, VITT S, PODDA A et al.: Development and Phase I clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine (1992) 10:691–698.
  • ANDERSON EL, BOWERS T, MINK CM et al.: Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. (1994) 62:3391–3395.
  • LIEBERMAN JM, CHIU SS, WONG VK et al.: Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children - a randomized controlled trial. /AMA (1996) 275:1499–1503.
  • TWUMASI PA JR, KUMAH S, LEACH Aet al.: A trial of a group A plus group C meningococcal polysaccharide- protein conjugate vaccine in African infants. J. Infect. Dis. (1995) 171:632–638.
  • •First meningococcal conjugate vaccine trial in West Africa.
  • FAIRLEY CK, BEGG N, BORROW R et al.: Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. (1996) 174:1360–1363.
  • LEACH A, TWUMASI PA, KUMAH S et al.: Induction of immunologic memory in gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide- protein conjugate vaccine. J. Infect. Dis. (1997) 175:200–204.
  • MACLENNAN J, OBARO S, DEEKS J et al.: Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis. (2001) 183:97–104.
  • HARRIS SL, FINN A, GRANDEE DM: Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect. Immun. (2003) 71:3402–3408.
  • CAMPAGNE G, GARBA A, FABRE P et al.: Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J. (2000) 19:144–150.
  • LAGOS R, VALENZUELA MT, LEVINE OS et al.: Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunoaffinity of fractional-dose and two-dose regimens. Lancet (1998) 351:1472–1476.
  • CHIPPAUX JP, GARBA A, ETHEVENAUX C et al.: Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine infants in Niger. Vaccine (2004) 22:3303–3311.
  • JOSEPH H, RYALL R, BYBEL M et al.: Immunogenicity and immunological priming of the serogroup A portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children./ Infect. Dis. (2003) 187:1142–1146.
  • ZHANG Q, LAKSHMAN R, BURKINSHAW R et al.: Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect. Immun. (2001) 69:4337–4341.
  • MAIDEN MC, STUART JM, UK MENINGOCOCCAL CARRIAGE GROUP: Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet (2002) 359: 1829-1830.
  • CAMPBELL JD, EDELMAN R, KING JC JR et al.: Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults./ Infect. Dis. (2002) 186:1848–1851.
  • RENNELS M, KING J JR, RYALL R et al.:Dose escalation, safety and immunogenicity study of a tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr. Infect. Dis. J. (2002) 21:978–979.
  • RENNELS M, KING J JR, RYALL R, PAPA T, FROESCHLE J: dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. (2004) 23:429–435.
  • •First reported infant studies with existing tetravalent meningococcal conjugate vaccine.
  • ROBBINS JB, SCHNEERSON R, GOTSCHLICH E et al.: Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull. World Health Organ. (2003) 81:745–750.
  • ••Documents the strengths of differentapproaches for the prevention of epidemic meningitis in sub-Saharan Africa.
  • LAFORCE FM: Control of epidemic meningitis in sub-Saharan Africa: our solution is more practical and affordable. Bull. World Health Organ. (2003) 81:753–754.
  • ••Documents the strengths of differentapproaches for the prevention of epidemic meningitis in sub-Saharan Africa.
  • ROBBINS JB, SCHNEERSON R, GOTSCHLICH EC: A rebuttal: epidemic and endemic meningococcal. meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr. Infect. Dis. J. (2000) 19:945–953.
  • CHIPPAUX JP, DEBOIS H, SALIOU P:A critical review of control strategies against meningococcal meningitis epidemics in sub-Saharan African countries. Infection (2002) 30:216–224.
  • ROBBINS JB, TOWNE DW, GOTSCHLICH EC, SCHNEERSON R: `Love's labours lost': failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet (1997) 350:880–882.
  • MILLER E, SALISBURY D, RAMSAY M: Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine (2001) 20\(Suppl. 1):S58–S67.
  • •Provides a road-map for licensure of a new vaccine for which the mechanism of protection is understood.
  • JODAR L, LAFORCE FM, CECCARINI C, AGUADO T, GRANOFF DM: Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet (2003) 361:1902–1904.
  • ••A new paradigm for how vaccines maybe produced.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.